{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:23:13Z","timestamp":1775060593897,"version":"3.50.1"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Immunotherapy has revolutionized cancer treatment, offering new hope for many patients. However, while some individuals show remarkable responses, the overall success rate remains limited. This has spurred interest in combination therapies, particularly with established treatments like radiation therapy (RT), to improve outcomes. RT is a cornerstone of cancer therapy and known to influence the immune landscape, yet a systematic characterization of its effects on tumor-infiltrating leukocytes (TILs) and a rationale-based therapy is still lacking. In this study, we employed a diverse set of pre-clinical syngeneic murine tumor models with varying immune profiles to investigate the immunological impact of tumor targeted RT. We observed that immunologically \u2018hot\u2019 tumors showed stronger tumor growth inhibition (TGI) after RT compared to \u2018cold\u2019 tumors. Additionally, RT induced both pro- and anti-inflammatory shifts within the tumor immune microenvironment. Importantly, RT led to an intra-tumoral increase in proliferating CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, while the population of proliferating macrophages was notably reduced. To identify immune-modulatory pathways that shape the response to RT across different tumor immune contexts, we tested RT in HPK1 (Hematopoietic Progenitor Kinase 1) and STING (Stimulator of Interferon Genes) deficient mice. These experiments revealed that STING deficiency compromises TGI in tumors with a high baseline population of myeloid cells expressing an interferon response signature. Moreover, we identified a synergistic effect on survival in tumor-bearing mice when combining HPK1 deficiency with RT. Thus, RT promotes expansion of cytotoxic T cells while limiting macrophage proliferation, with therapeutic outcomes strongly influenced by STING and HPK1 pathways. Collectively, these results highlight the complex interplay between RT, tumor immune microenvironment and response to therapy, offering potential avenues for novel therapeutic combinations.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1637129","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T10:02:29Z","timestamp":1774605749000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Rational modulation of immune mechanisms synergizes the anti-tumor effects of targeted radiation therapy in pre-clinical models"],"prefix":"10.3389","volume":"17","author":[{"given":"Tristan","family":"Wirtz","sequence":"first","affiliation":[{"name":"Oncology R&D, Pfizer Inc","place":["La Jolla, CA, United States"]},{"name":"Animal Models and Imaging, Comparative Medicine-Drug Safety R&D, Pfizer Inc","place":["La Jolla, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Lee","sequence":"additional","affiliation":[{"name":"Oncology R&D, Pfizer Inc","place":["La Jolla, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sripad","family":"Ram","sequence":"additional","affiliation":[{"name":"Global Pathology, Comparative Medicine-Drug Safety R&D, Pfizer Inc","place":["La Jolla, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Xie","sequence":"additional","affiliation":[{"name":"Oncology R&D, Pfizer Inc","place":["La Jolla, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sepideh","family":"Mojtahedzadeh","sequence":"additional","affiliation":[{"name":"Global Pathology, Comparative Medicine-Drug Safety R&D, Pfizer Inc","place":["La Jolla, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Streiner","sequence":"additional","affiliation":[{"name":"Oncology R&D, Pfizer Inc","place":["La Jolla, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavon","family":"Noorbehesht","sequence":"additional","affiliation":[{"name":"Animal Models and Imaging, Comparative Medicine-Drug Safety R&D, Pfizer Inc","place":["La Jolla, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa K.","family":"Manzuk","sequence":"additional","affiliation":[{"name":"Animal Models and Imaging, Comparative Medicine-Drug Safety R&D, Pfizer Inc","place":["La Jolla, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Rohner","sequence":"additional","affiliation":[{"name":"Oncology R&D, Pfizer Inc","place":["La Jolla, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Cabral","sequence":"additional","affiliation":[{"name":"Animal Models and Imaging, Comparative Medicine-Drug Safety R&D, Pfizer Inc","place":["La Jolla, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicius","family":"Bonato","sequence":"additional","affiliation":[{"name":"Non-Clinical Statistics, Worldwide Research & Development (WRD), Pfizer Inc","place":["La Jolla, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Affolter","sequence":"additional","affiliation":[{"name":"Global Pathology, Comparative Medicine-Drug Safety R&D, Pfizer Inc","place":["La Jolla, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Kraus","sequence":"additional","affiliation":[{"name":"Oncology R&D, Pfizer Inc","place":["La Jolla, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Dillon","sequence":"additional","affiliation":[{"name":"Oncology R&D, Pfizer Inc","place":["La Jolla, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Giddabasappa","sequence":"additional","affiliation":[{"name":"Animal Models and Imaging, Comparative Medicine-Drug Safety R&D, Pfizer Inc","place":["La Jolla, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nrclinonc.2012.203","article-title":"Past, present, and future of radiotherapy for the benefit of patients","volume":"10","author":"Thariat","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrclinonc.2009.188","article-title":"Stereotactic body radiation therapy: a novel treatment modality","volume":"7","author":"Lo","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70510-7","article-title":"Stereotactic body radiotherapy for oligometastases","volume":"14","author":"Tree","year":"2013","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.120","article-title":"Opportunities and challenges of radiotherapy for treating cancer","volume":"12","author":"Schaue","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2288","article-title":"Innovations in image-guided radiotherapy","volume":"7","author":"Verellen","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0942-3","article-title":"Radiation-induced bystander and abscopal effects: important lessons from preclinical models","volume":"123","author":"Daguenet","year":"2020","journal-title":"Br J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2217\/imt.14.38","article-title":"Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy","volume":"6","author":"Gaipl","year":"2014","journal-title":"Immunotherapy"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose","volume":"9","author":"Demaria","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.30","article-title":"Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach","volume":"13","author":"Bernstein","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1101\/gad.10.18.2251","article-title":"Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK\/SAPK kinase cascade","volume":"10","author":"Hu","year":"1996","journal-title":"Genes Dev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nature08476","article-title":"STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity","volume":"461","author":"Ishikawa","year":"2009","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb01093.x","article-title":"HPK1, a hematopoietic protein kinase activating the SAPK\/JNK pathway","volume":"15","author":"Kiefer","year":"1996","journal-title":"EMBO J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S1074-7613(00)80192-2","article-title":"HPK1 is activated by lymphocyte antigen receptors and negatively regulates AP-1","volume":"12","author":"Liou","year":"2000","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Sun","year":"2013","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.1229963","article-title":"Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA","volume":"339","author":"Wu","year":"2013","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.55122","article-title":"A perspective on HPK1 as a novel immuno-oncology drug target","volume":"9","author":"Sawasdikosol","year":"2020","journal-title":"Elife"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00468-w","article-title":"The cGAS-STING pathway and cancer","volume":"3","author":"Samson","year":"2022","journal-title":"Nat Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.12.060","article-title":"Volumetric imaging of optically cleared and fluorescently labeled animal tissue (VIOLA) for quantifying the 3D biodistribution of nanoparticles at cellular resolution in tumor tissue","volume":"354","author":"Rakhilin","year":"2023","journal-title":"J Control Release"},{"key":"B33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-4672","article-title":"Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes","volume":"70","author":"Movahedi","year":"2010","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.smim.2017.12.004","article-title":"Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells","volume":"35","author":"Zhou","year":"2018","journal-title":"Semin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.04.004","article-title":"MDSC: Markers, development, states, and unaddressed complexity","volume":"54","author":"Hegde","year":"2021","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8(+) T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201344272","article-title":"Effect of tumor cells and tumor microenvironment on NK-cell function","volume":"44","author":"Vitale","year":"2014","journal-title":"Eur J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12737","article-title":"Ageing adversely affects the migration and function of marginal zone B cells","volume":"151","author":"Turner","year":"2017","journal-title":"Immunology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-120419-022408","article-title":"Germinal centers","volume":"40","author":"Victora","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","article-title":"B cells, plasma cells and antibody repertoires in the tumour microenvironment","volume":"20","author":"Sharonov","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nri3307","article-title":"Transcriptional control of effector and memory CD8+ T cell differentiation","volume":"12","author":"Kaech","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","article-title":"TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision","volume":"51","author":"Chen","year":"2019","journal-title":"Immunity"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01219-w","article-title":"\u2018Stem-like\u2019 precursors are the fount to sustain persistent CD8(+) T cell responses","volume":"23","author":"Zehn","year":"2022","journal-title":"Nat Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.immuni.2019.11.002","article-title":"Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1(+) stem-like CD8(+) T cells during chronic infection","volume":"51","author":"Hudson","year":"2019","journal-title":"Immunity"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653974","article-title":"To ki or not to ki: re-evaluating the use and potentials of ki-67 for T cell analysis","volume":"12","author":"Di Rosa","year":"2021","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","article-title":"The Ki-67 protein: from the known and the unknown","volume":"182","author":"Scholzen","year":"2000","journal-title":"J Cell Physiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"108115","DOI":"10.1016\/j.celrep.2020.108115","article-title":"Baseline frequency of inflammatory cxcl9-expressing tumor-associated macrophages predicts response to avelumab treatment","volume":"32","author":"Qu","year":"2020","journal-title":"Cell Rep"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/s41467-017-01566-5","article-title":"Host STING-dependent MDSC mobilization drives extrinsic radiation resistance","volume":"8","author":"Liang","year":"2017","journal-title":"Nat Commun"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00999-10","article-title":"The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides","volume":"79","author":"Sauer","year":"2011","journal-title":"Infect Immun"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/ni1416","article-title":"Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell-mediated immune responses","volume":"8","author":"Shui","year":"2007","journal-title":"Nat Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.6.2364-2383.2005","article-title":"Activation of hematopoietic progenitor kinase 1 involves relocation, autophosphorylation, and transphosphorylation by protein kinase D1","volume":"25","author":"Arnold","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M707425200","article-title":"Prostaglandin E2 activates HPK1 kinase activity via a PKA-dependent pathway","volume":"282","author":"Sawasdikosol","year":"2007","journal-title":"J Biol Chem"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e0212670","DOI":"10.1371\/journal.pone.0212670","article-title":"Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance","volume":"14","author":"Liu","year":"2019","journal-title":"PloS One"},{"key":"B65","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.celrep.2018.09.012","article-title":"The kinase activity of hematopoietic progenitor kinase 1 is essential for the regulation of T cell function","volume":"25","author":"Hernandez","year":"2018","journal-title":"Cell Rep"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e0206223","DOI":"10.1371\/journal.pone.0206223","article-title":"Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments","volume":"13","author":"Yu","year":"2018","journal-title":"PloS One"},{"key":"B67","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1158\/2326-6066.CIR-16-0114","article-title":"Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery","volume":"5","author":"Mosely","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1667\/RR13500.1","article-title":"The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation","volume":"182","author":"Demaria","year":"2014","journal-title":"Radiat Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000436722.46675.4a","article-title":"Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy","volume":"36","author":"Lechner","year":"2013","journal-title":"J Immunother"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0044","article-title":"Mouse models for cancer immunotherapy research","volume":"8","author":"Olson","year":"2018","journal-title":"Cancer Discov"},{"key":"B72","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.4287","article-title":"Towards the introduction of the \u2018Immunoscore\u2019 in the classification of Malignant tumours","volume":"232","author":"Galon","year":"2014","journal-title":"J Pathol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/0167-5699(87)90852-8","article-title":"Total lymphoid irradiation","volume":"8","author":"Slavin","year":"1987","journal-title":"Immunol Today"},{"key":"B75","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2307\/3579443","article-title":"A versatile and rapid assay of radiosensitivity of peripheral blood leukocytes based on DNA and surface-marker assessment of cytotoxicity","volume":"147","author":"Crompton","year":"1997","journal-title":"Radiat Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1383-5718(01)00290-X","article-title":"Differential apoptotic response to ionizing radiation in subpopulations of human white blood cells","volume":"513","author":"Wilkins","year":"2002","journal-title":"Mutat Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment","volume":"114","author":"Lee","year":"2009","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2982","article-title":"Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy","volume":"70","author":"Takeshima","year":"2010","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3427","article-title":"Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1038\/s41467-024-49873-y","article-title":"Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease","volume":"15","author":"Telarovic","year":"2024","journal-title":"Nat Commun"},{"key":"B81","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0065-2776(08)60331-4","article-title":"Ionizing radiation and the immune response","volume":"24","author":"Anderson","year":"1976","journal-title":"Adv Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830241150","article-title":"Ionizing radiation induces apoptotic cell death in human TcR-gamma\/delta+ T and natural killer cells without detectable p53 protein","volume":"24","author":"Seki","year":"1994","journal-title":"Eur J Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"},{"key":"B84","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/ijms21134585","article-title":"Brachytherapy in a single dose of 10Gy as an \u201cin situ\u201d Vaccination","volume":"21","author":"Jarosz-Biej","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1667\/RR0978.1","article-title":"Gamma-ray resistance of regulatory CD4+CD25+Foxp3+ T cells in mice","volume":"173","author":"Qu","year":"2010","journal-title":"Radiat Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.09.034","article-title":"Radiation enhances regulatory T cell representation","volume":"81","author":"Kachikwu","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B87","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1158\/2326-6066.CIR-17-0040","article-title":"Stereotactic radiotherapy increases functionally suppressive regulatory T cells in the tumor microenvironment","volume":"5","author":"Muroyama","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.7.3760","article-title":"Differential sensitivity of naive and memory CD8+ T cells to apoptosis in vivo","volume":"169","author":"Grayson","year":"2002","journal-title":"J Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1038\/s41467-019-11906-2","article-title":"Tumor-reprogrammed resident T cells resist radiation to control tumors","volume":"10","author":"Arina","year":"2019","journal-title":"Nat Commun"},{"key":"B90","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","article-title":"Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer","volume":"181","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"B91","doi-asserted-by":"publisher","first-page":"abe6474","DOI":"10.1126\/science.abe6474","article-title":"Pan-cancer single-cell landscape of tumor-infiltrating T cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B94","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"B97","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/sciimmunol.abg0117","article-title":"Sequence of alphaPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses","volume":"6","author":"Wei","year":"2021","journal-title":"Sci Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1673","article-title":"Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade","volume":"23","author":"Dovedi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1836-5","article-title":"An intra-tumoral niche maintains and differentiates stem-like CD8 T cells","volume":"576","author":"Jansen","year":"2019","journal-title":"Nature"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.immuni.2021.08.026","article-title":"Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1(+) CD8(+) T cells in tumor-draining lymph nodes","volume":"54","author":"Schenkel","year":"2021","journal-title":"Immunity"},{"key":"B101","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","article-title":"The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes","volume":"185","author":"Huang","year":"2022","journal-title":"Cell"},{"key":"B102","doi-asserted-by":"publisher","first-page":"eabg7836","DOI":"10.1126\/sciimmunol.abg7836","article-title":"A reservoir of stem-like CD8(+) T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response","volume":"6","author":"Connolly","year":"2021","journal-title":"Sci Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"key":"B104","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.immuni.2022.12.002","article-title":"CD8(+) T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor","volume":"56","author":"Prokhnevska","year":"2023","journal-title":"Immunity"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J Exp Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J Exp Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401869","article-title":"STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells","volume":"193","author":"Klarquist","year":"2014","journal-title":"J Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep"},{"key":"B111","doi-asserted-by":"publisher","first-page":"15385","DOI":"10.1038\/s41598-020-72393-w","article-title":"Cellular uptake of extracellular nucleosomes induces innate immune responses by binding and activating cGMP-AMP synthase (cGAS)","volume":"10","author":"Wang","year":"2020","journal-title":"Sci Rep"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/nature23470","article-title":"Mitotic progression following DNA damage enables pattern recognition within micronuclei","volume":"548","author":"Harding","year":"2017","journal-title":"Nature"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1621363114","article-title":"cGAS is essential for the antitumor effect of immune checkpoint blockade","volume":"114","author":"Wang","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B114","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ccell.2020.11.006","article-title":"DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity","volume":"39","author":"Lu","year":"2021","journal-title":"Cancer Cell"},{"key":"B115","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ccell.2020.11.004","article-title":"MLH1 deficiency-triggered DNA hyperexcision by exonuclease 1 activates the cGAS-STING pathway","volume":"39","author":"Guan","year":"2021","journal-title":"Cancer Cell"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"B117","doi-asserted-by":"publisher","first-page":"eadd7446","DOI":"10.1126\/sciimmunol.add7446","article-title":"Rapid recruitment and IFN-I-mediated activation of monocytes dictate focal radiotherapy efficacy","volume":"8","author":"Tadepalli","year":"2023","journal-title":"Sci Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-02041-6","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct Target Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1637129\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:40:58Z","timestamp":1775054458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1637129\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":119,"alternative-id":["10.3389\/fimmu.2026.1637129"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1637129","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"article-number":"1637129"}}